Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …

Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million
cases in children younger than 5 years, with 10% requiring hospital admission and up to …

Abstract Introduction The REGAL (RSV Evidence–A Geographical Archive of the Literature)
series has provided a comprehensive review of the published evidence in the field of …

A stabilized form of the respiratory syncytial virus (RSV) fusion (F) protein has been explored
as a vaccine to prevent viral infection because it presents several potent neutralizing …

Respiratory syncytial virus (RSV) is primarily associated with respiratory disorders globally.
Despite the availability of information, there is still no competitive vaccine available for RSV …

Community-acquired pneumonia (CAP) is an important respiratory disease and the fifth
leading cause of mortality in Europe. The development of molecular diagnostic tests has …

Background Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory
infection globally. There are vaccine candidates in development, but a systematic review on …

Subunit vaccines are composed of pathogen fragments that, on their own, are generally
poorly immunogenic. Therefore, the incorporation of an immunostimulating agent, eg …

Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in
infants and it also induces significant disease in the elderly. The clinical course may be …

Utilizing nanoparticles to deliver subunit vaccines can be viewed as a promising strategy for
enhancing the immune response, especially with regard to cellular immunity to fight against …